Pfizer and Chiesi-backed genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.
4D Molecular Therapeutics (4DMT), the US-based gene therapy developer backed by pharmaceutical firms Chiesi Group and Pfizer, withdrew its application for an initial public offering on Tuesday.
Founded in 2013, 4DMT is working on adeno-associated virus-based treatments for a genetic disorder known as Fabry disease, in addition to retinal conditions retinitis pigmentosa and choroideremia, and cystic fibrosis-related lung disease.
The company filed for a $100m IPO in September 2019 but had not set a price range for the…
